COMP <GO>
AXGN vs MRK // FORWARD P/E MULTIPLE
Axogen Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: AXGN 5
— MRK 9
▲ FORWARD P/E MULTIPLE LEADER: AXGN
LAST: $49.37 (-0.52%) • MKT CAP: $2.96B
forward-pe
18.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXGN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXGN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 74.80% | -0.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.60% | 20.70% | -23.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.10% | 3.42% | -3.52 | MRK | /fcf-yield <GO> |
| Operating Margin | -3.50% | 34.30% | -37.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | -7.00% | 28.10% | -35.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 1.30% | +18.90 | AXGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.64 | 5.19 | +13.45 | AXGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 73.9 | 56.9 | +17.07 | AXGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.92 | +0.18 | AXGN | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 18.0x | 18.4x | -0.40 | AXGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.96B | $361.02B | -$358.06B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXGN REV | MRK REV | AXGN GROSS % | MRK GROSS % | AXGN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $225.2M | $65.01B | 74.3% | 74.8% | -$2.9M | $12.36B |
| FY 2024 | $187.3M | $64.17B | 75.8% | 76.3% | $1.4M | $18.10B |
| FY 2023 | $159.0M | $60.12B | 44.0% | 44.0% | -$12.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXGN // BETA 1.10
MRK // BETA 0.92